Johnson & Johnson Pharmaceutical Research & Development Submits New Drug Application for Paliperidone... ( TITUSVILLE N.J. Oct. 29 /- Johnso...)

Johnson & Johnson Pharmaceutical Research & Development Submits New Drug Application for Paliperidone Palmitate

Date:10/29/2007

TITUSVILLE, N.J., Oct. 29 /PRNewswire/ -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for paliperidone palmitate, an investigational, once-monthly atypical antipsychotic intramuscular injection, for the treatment of schizophrenia and the prevention of recurrence of the symptoms of schizophrenia.

Paliperidone palmitate is a long-acting injectable ester of the active ingredient in INVEGA(TM)(1) which utilizes Elan's NanoCrystal(R) Technology. Upon approval, paliperidone palmitate will be marketed in the U.S. by Janssen, L.P.

Worldwide, it is estimated that one person in every 100 develops schizophrenia, one of the most serious types of mental illness. In the United States, there are currently 2,000,000 people with schizophrenia, with men and women affected equally. The disease is marked by positive symptoms (hallucinations and delusions) and negative symptoms (depression, blunted emotions, and social withdrawal), as well as by disorganized thinking.

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) is headquartered in Raritan, New Jersey (USA), and has nine sites throughout Europe and the United States. J&JPRD employs approximately 3,500 people and is leveraging drug discovery, drug evaluation, and drug development in a variety of therapeutic areas to address unmet medical needs worldwide. The company's major therapeutic areas of focus include hematology, oncology, infectious disease, obesity and metabolic disorders, neurology and psychiatry, pain and women's health.

Janssen, L.P., based in Titusville, N.J., is a subsidiary of Johnson & Johnson, and is the only pharmaceutical company in the U.S. dedicated solely to mental health. The company currently markets prescription medications for the treatment of schizophrenia, bipolar mania, and irritability associated with autistic disorder. F
'/>"/>

1

GOOD

Page: 1 2 3 4 5
Related medicine news :

1. Robert Wood Johnson Foundation Pledges $500M To Fund Anti-Obesity Programs
2. South Africa Wins landmark case against pharmaceutical giants
3. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
4. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
5. Setting up a new pharmaceutical industry in India
6. Medicis Pharmaceutical company enters pediatric market
7. Supply of Radiopharmaceuticals Hampered by Attacks
8. Pharmaceutical companies are targeting patients
9. FDA approves Watson Pharmaceuticals Oxytrol patch
10. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
11. Indian Pharmaceutical Industries Stops Manufacturing And Sale Of Valdecoxib

Post Your Comments:

Johnson & Johnson Pharmaceutical Research & Development Submits New Drug Application for Paliperidone...( TITUSVILLE N.J. Oct. 29 /- Johnso...),Health